Profil
Kerry Russell worked as Vice President-Clinical Development at Dicerna Pharmaceuticals, Inc. from 2020 to 2022.
Dr. Russell also held the same position at resTORbio, Inc. Dr. Russell then became the Chief Medical Officer-Metabolic at Terns Pharmaceuticals, Inc. in 2023.
Dr. Russell completed an undergraduate degree at Rice University and obtained doctorate degrees from The University of Texas at Austin and The University of Texas Health Science Center at Houston.
Ehemalige bekannte Positionen von Kerry Russell
| Unternehmen | Position | Ende |
|---|---|---|
| TERNS PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2023 |
| DICERNA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.05.2022 |
| DICERNA PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| ADICET BIO, INC. | Corporate Officer/Principal | - |
Ausbildung von Kerry Russell
| Rice University | Undergraduate Degree |
| The University of Texas at Austin | Doctorate Degree |
| The University of Texas Health Science Center at Houston | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| TERNS PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
resTORbio, Inc.
 resTORbio, Inc. BiotechnologyHealth Technology resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA. | Health Technology |
Dicerna Pharmaceuticals, Inc.
 Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA. | Health Technology |
